Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J3262 |
Short Description | Tocilizumab injection |
Long Description | Injection, tocilizumab, 1 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2011-01-01 |
Date Added | 2011-01-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
50242013501 | J3262 | Tocilizumab injection | Actemra | GENENTECH, INC. | 1 MG | 4 | 1 | 80 | 80 |
50242013601 | J3262 | Tocilizumab injection | Actemra | GENENTECH, INC. | 1 MG | 10 | 1 | 200 | 200 |
50242013701 | J3262 | Tocilizumab injection | Actemra | GENENTECH, INC. | 1 MG | 20 | 1 | 400 | 400 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Tocilizumab injection is used alone or in combination with other medications to relieve the symptoms of certain types of arthritis and other conditions including:
-
rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have not been helped by other disease-modifying antirheumatic drugs (DMARDs),
-
giant cell arteritis (a condition that causes swelling of blood vessels, especially in the scalp and head) in adults,
-
systemic sclerosis-associated interstitial lung disease (SSc-ILD; also known as scleroderma-associated ILD: a lung disease that involves scarring of the lungs) in adults,
-
polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age or older.
-
systemic juvenile idiopathic arthritis (SJIA; a condition in children that causes inflammation in different areas of the body, causing fever, joint pain and swelling, loss of function, and delays in growth and development) in children 2 years of age or older,
-
cytokine release syndrome (a severe and possibly life-threatening reaction) in adults and children 2 years of age or older after receiving certain immunotherapy infusions.
-
-
Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.